Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

3.240 -0.010 (-0.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aquestive Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Friday? ↗
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Shoe Carnival, American Eagle, Ciena, Victoria's Secret And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film ↗
Via Stocktwits
News headline image
FDA Confirms Direct Review Path For Aquestive's Allergy Treatment ↗
Aquestive's Anaphylm could become the first oral epinephrine for severe allergic reactions after the FDA set a 2026 decision date without panel review. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail ↗
Via Stocktwits
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Uncovering Potential: Aquestive Therapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Uncovering Potential: Aquestive Therapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data ↗
Aquestive's Anaphylm sublingual film met key pediatric study goals, supporting its NDA submission to the FDA for potential approval in 2025. 
Via Benzinga
News headline image
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.